Mark Egerton

Biography

 Dr. Mark Egerton serves as the Chief Executive Officer and Managing Director of Quotient Clinical Limited since August 2005. Dr. Egerton serves as Chief Commercial Officer of Oxagen Limited. He serves as Managing Director of Pharmaceutical Profiles Group Ltd. He served as Vice President of European business operations with Incyte Genomics Limited, based in Cambridge. He served as Vice President of Research and Development for pharmacogenomics with Incyte Genomics Inc. (based in Palo Alto, California). He served as Chief Executive Officer of Cyprotex PLC. He served as Chief Business Officer of Oxagen Limited. His career to date has spanned 12 years in the pharmaceutical and biotechnology industries, during which time he has gained a great depth of knowledge of the drug discovery process and the pharmaceutical industry. Dr. Egerton began his pharmaceutical R&D career at Sandoz (now Novartis) in Switzerland and then Zeneca (now AstraZeneca) in the UK. During this time he was responsible for Discovery projects across a number of therapeutic areas including Inflammation, Infectious disease, and Metabolic disease. He has over 17 years' experience in the pharmaceutical and biotech industry and has worked in a range of organizations including large multinational pharmaceutical companies through to private venture funded biotechnology companies. Dr. Egerton serves as Director of Quotient Clinical Limited. He served as Director of Cyprotex PLC until September 1, 2003. He holds PhD in Biochemistry from University of Edinburgh and post-doctoral research in Biochemistry, Biozentrum, Basel.

Research Interest

 Pharmaceutical Sciences